Abstract:

Cyclophosphamide (CTX), an alkylating agent, is widely used as an immunosuppressive agent and antitumor drug. Because of abundant clinical research evidences, KDIGO recommended CTX as the preferred treatment for idiopathic membranous nephropathy(IMN), recommend level 1B. However, due to the carcinogenesis and other side effects, the dose and method of CTX treatment of IMN is still under controversy. This article will review the mechanism, clinical efficacy, safety, medication pathways and the differences from other IMN medicines of cyclophosphamide.

Key words: cyclophosphamide, idiopathic membranous nephropathy